Deregulation of translation initiation factors contributes to many pathogenic conditions including cancer. Here we report the definition of a novel regulatory pathway for translational initiation with possible therapeutic import in cancer. Specifically, we found that casein kinase 1 İ (CK1İ) is highly expressed in breast tumors and plays a critical role in cancer cell proliferation by controlling mRNA translation. Eukaryotic translation initiation factor eIF4E, an essential component of the translation initiation complex eIF4F, is downregulated by binding the negativeacting factor 4E-BP1. We found that genetic or pharmacological inhibition of CK1İ attenuated 4E-BP1 phosphorylation, thereby increasing 4E-BP1 binding to eIF4E and inhibiting mRNA translation. Mechanistic investigations showed that CK1İ interacted with and phosphorylated 4E-BP1 at two novel sites T41 and T50, which were essential for 4E-BP1 inactivation along with increased mRNA translation and cell proliferation. In summary, our work identified CK1İ as a pivotal regulator of mRNA translation and cell proliferation that acts by inhibiting 4E-BP1 function. As CK1İ is highly expressed in breast tumors, these findings offer an initial rationale to explore CK1İ blockade as a therapeutic strategy to treat cancers driven by deregulated mRNA translation.
Introduction
mRNA translation plays a critical role in the control of cellular processes to modulate cell growth, cell size, and cell proliferation (1) (2) . In eukaryotic cells, the majority of mRNA translation occurs in a cap-dependent manner, meaning that it relies on a complex of proteins that assemble at the 7-methylguanosine (m 7 G) cap at the 5' end of mRNA (3) . mRNA translation is principally regulated at the initiation stage rather than the elongation or termination step, which enables rapid, reversible and spatial control of gene expression (2, (4) (5) . Therefore, translation initiation in eukaryotes is highly regulated (4) .
The best established mechanism of controlling translation initiation is through regulation of the eIF4F complex that is comprised of eIF4E, eIF4A, and eIF4G (5) . Translation initiation starts when the eIF4F complex binds to the m 7 G cap of mRNA and recruits the 40S ribosome (3, 6) . Formation of the eIF4F complex is dependent on the bioavailability of eIF4E, a major capbinding protein. eIF4E is considered a key factor in mRNA translation, since the eIF4F complex is the major regulator of translation initiation, and initiation is a major rate-limiting step of translation (2) (3) . eIF4E is known to be mainly regulated by the eIF4E inhibitory binding proteins (4E-BPs). 4E-BP1 is the major form of the three isoforms of 4E-BPs. 4E-BP1 negatively regulates protein synthesis by binding to and inhibiting eIF4E. The unphosphorylated or hypophosphorylated form of 4E-BP1 is active and inhibits eIF4E function. Phosphorylation of 4E-BP1 relieves its binding to eIF4E, allowing eIF4E to start mRNA translation (6) (7) . Therefore, 4E-BP1 is a critical negative regulator of protein synthesis (6) .
The best characterized signaling pathway that regulates mRNA translation is the mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) pathway. Activation of mTORC1 plays a significant role in translational control and cell proliferation by regulating 4E-BP1 phosphorylation (1) . However, recent studies show that allosteric inhibitors of mTORC1 (e.g. rapamycin) and ATP-competitive mTOR inhibitors (e.g. PP242 and WYE354) do not substantially inhibit 4E-BP1 phosphorylation and cell proliferation in many cell types (8) (9) (10) . Because 4E-BP1 has many phosphorylation sites, but mTORC1 is known to regulate only a few of them, it is plausible to assume that there may be kinases other than mTORC1 that regulate mRNA translation and cell proliferation through regulation of 4E-BP1 phosphorylation.
Identification of these kinases is essential for further understanding of signaling-mediated protein synthesis.
We were interested in kinases involved in the regulation of circadian rhythm that is regulated by oscillations of transcription/translation. Circadian rhythm and protein synthesis regulate cellular metabolism, cell cycle progression, and cell proliferation. Aberrance of these processes leads to metabolism-related diseases such as cancer and diabetes, and change of life span (1, (11) (12) (13) . A recent study revealed that circadian rhythm coordinates mRNA translation through regulation of ribosome biogenesis (14) . Therefore, we were curious if the kinases that regulate circadian rhythm could control mRNA translation. CK1 is the key kinase that regulates circadian rhythm (11) (12) 15) . The CK1 family consists of several isoforms, such as CK1Į, CK1į, CK1İ, and CK1Ȗ. These isoforms share highly conserved kinase domains, but differ significantly in non-catalytic domains, suggesting that each isoform may play a specific role in regulating biological processes (16) . Growing evidence suggests that circadian rhythm is closely related to cancer, although the exact mechanisms of this relationship are not established yet. It is known that deregulation of circadian rhythm promotes tumor development and progression (11) (12) . In addition, the genetic and/or functional disruption of the molecular circadian rhythm is found in various cancers (17) . Because of the essential roles of circadian rhythm on cell metabolism and cell proliferation, the key molecules that regulate circadian rhythm may also play critical roles in tumor progression (11) (12) 18 ). In fact, some CK1 isoforms were recently identified as tumor promoters (19) . However, the molecular mechanisms by which these CK1s promote tumor progression have not been fully understood. Here we provide strong evidence that CK1İ is a key regulator of cell proliferation by modulating protein synthesis. Our data shows that CK1İ Protein phosphotransferase assay. For the CK1İ kinase assay using 4E-BP1 as the substrate, HEK293 cells were transfected with pcDNA3-HA-4E-BP1 WT or T41A/T50A mutant for 2 days and treated for 2 h with LY294002, a PI3-kinase pathway inhibitor. Cells were lysed with buffer A (20 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate, 1 mM sodium orthovanadate, 5 mM NaF, 2 mM phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin, and 1mg/ml pepstatin) containing 1% Triton X-100, and immunoprecipitation was performed using an HA antibody immobilized onto sepharose matrix products were subjected to SDS-PAGE, and dried gel was autoradiographed. For the CK1İ kinase assay using recombinant His-4E-BP1 purified from E.coli strain SG13009, the same reaction buffer, time, and temperature were used.
Cap-binding assay. Cap-binding assay and bicistronic luciferase assay were performed as described previously (22). 
Results
CK1İ plays an essential role in cell proliferation. We were interested in determining the effect of different CK1 isoforms on the proliferation of HEK293 cells that are known to express CK1Į, CK1į, CK1İ, and CK1Ȗ (25) (26) . Using shRNA to knockdown these isoforms (Fig. S1 ), we found that CK1İ is the most potent regulator of cell proliferation (Fig. 1A) . We then determined if the CK1İ knockdown effect on cell proliferation was due to increased cell death.
As shown in Fig. 1B , there was no significant difference in cell death between knockdown and control cells. We next treated cells with a CK1İ inhibitor, PF-670462, and found that this inhibitor dramatically decreased cell proliferation ( Fig. 1C ) without inducing significant cell death (Fig. S2 ). We also used the HCC1806 breast cancer cell line to confirm that CK1İ is a critical regulator of cell proliferation. As shown in Fig. 1D and 1E, knockdown of CK1İ or CK1İ inhibitor treatment significantly decreased cell proliferation.
We next determined whether CK1İ is overexpressed in cancers using the Human Protein Atlas (www.proteinatlas.org), a database of protein expression profiles based on immunohistochemistry of a large number of human cancer tissues. As shown in Fig. S3 , CK1İ is more highly expressed in breast cancer than in normal tissues. In addition, we performed immunohistochemistry on microarrays of normal and breast tumor tissues, and similarly found that CK1İ is overexpressed in breast cancer (Fig. 1F) . To determine the function of CK1İ in tumor growth, we used a mouse xenograft model with stable control or CK1İ knockdown HCC1806 breast cancer cell lines. As shown in Figs. 1G and 1H, CK1İ knockdown cells showed a dramatic reduction in tumor growth. Taken together, these results suggest that CK1İ is a critical regulator of breast cancer cell growth.
CK1İ regulates protein synthesis. To determine the mechanism by which CK1İ regulates cell proliferation, we assessed whether CK1İ could modulate global protein synthesis. We first examined polysome profiles and found that knockdown of CK1İ ( with CK1İ inhibitor (Fig. 2B ) significantly decreased polysome assembly. To further confirm this, we determined the effect of CK1İ on nascent protein synthesis. As shown in Fig. 2C , inhibition of CK1İ profoundly decreased nascent protein synthesis. These results suggest that CK1İ plays a major role in regulating mRNA translation.
CK1İ is a key player in cap-dependent translation. To determine whether CK1İ was involved in cap-dependent translation, we used a dual-luciferase reporter system that monitors the ratio between cap-dependent (Renilla luciferase) and cap-independent IRES (Firefly luciferase) translation initiation (9) . Knockdown of CK1İ (Fig. 3A) or treatment of cells with CK1İ inhibitor (Fig. 3B ) decreased the relative cap-dependent translation rate. Cap-dependent translation is mainly regulated by the availability of eIF4E that is controlled by its phosphorylation at Ser209 and by its inhibitory binding protein (4E-BPs). We first determined the phosphorylation status of eIF4E. Neither CK1İ knockdown (Fig. 3C ) nor inhibitor treatment (Fig. 3D ) changed its phosphorylation. We next explored the function of CK1İ in binding of 4E-BP1 to eIF4E on the cap. For this, we used 7-methyl GTP Sepharose beads in which 7-methyl GTP mimics the cap at the 5' end of mRNA. Although CK1İ knockdown (Fig. 3E) or treatment with CK1İ inhibitor (Fig. 3F) did not appreciably change the amount of 7-methyl GTP-bound eIF4E, it dramatically increased binding of 4E-BP1 to 7-methyl GTP. It is known that stimulation of cells with growth factors or hormones induces eIF4E and 4E-BP1 dissociation, thereby increasing eIF4E activity.
To determine whether inhibition of CK1İ blocks dissociation of 4E-BP1 from eIF4E, cells were maintained in the absence of serum and treated with insulin. As shown in Fig. 3G , 4E-BP1 and eIF4E remained associated when stimulated with insulin in the presence of the CK1İ inhibitor.
Taken together, our results suggest that CK1İ knockdown or inhibitor treatment decreases capdependent translation by increasing the binding of 4E-BP1 and eIF4E. CK1İ regulates 4E-BP1 activity through phosphorylation of 4E-BP1. The binding of 4E-BP1 to eIF4E depends on 4E-BP1 phosphorylation. It is known that Thr37/Thr46 must be phosphorylated first, followed by Thr70 phosphorylation. Lastly, Ser65 is phosphorylated, and then 4E-BP1 becomes inactive and dissociates from eIF4E (27) (28) . Based on our findings that CK1İ regulates binding of 4E-BP1 to eIF4E, we were curious if CK1İ regulated phosphorylation of 4E-BP1. To determine this, we examined 4E-BP1 phosphorylation at S65, the last phosphorylation site essential for 4E-BP1 activity. As shown in Fig. 4A , only the CK1İ knockdown decreased 4E-BP1 phosphorylation at S65. Using CK1İ knockdown cells and inhibitor treated cells, we determined phosphorylation of the other well-known phosphorylation sites. As shown in Figs. 4B and 4C, inhibition of CK1İ decreased 4E-BP1 phosphorylation at all sites examined, suggesting that 4E-BP1 is active and binds to eIF4E under these conditions as shown in Figs. 3E-3G. We next examined the effect of CK1İ inhibition on the phosphorylation of 4E-BP1 after insulin treatment. As shown in Fig. 4D , CK1İ inhibitor treatment blocked S65 phosphorylation. We examined the same phenomena in HCC1806 cells. CK1İ knockdown (Fig.   4E ) or inhibitor treatment (Fig. 4F ) decreased 4E-BP1 phosphorylation.
CK1İ regulates 4E-BP1 activity by phosphorylation at T41/T50. We were interested in the mechanism by which CK1İ regulates 4E-BP1 phosphorylation. The major regulator of 4E-BP1 phosphorylation is mTORC1. To determine whether CK1İ could regulate mTORC1, we examined phosphorylation of ribosomal protein S6 kinase 1 (S6K1), a direct downstream target of mTORC1, which is used as a readout of mTORC1 activity. As shown in Figs. 5A and 5B, neither knockdown of CK1İ nor CK1İ inhibitor treatment changed S6K1 phosphorylation. We also measured phosphorylation of Akt and ERK1/2, the main upstream regulators of mTORC1, and PRAS40 and Raptor, the direct regulators of mTORC1 activity by binding to mTORC1.
Knockdown of CK1İ (Fig. 5C ) or CK1İ inhibitor treatment (Fig. 5D) 
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suggests that other mechanisms may exist for CK1İ to regulate 4E-BP1 phosphorylation. To determine if CK1İ could be a direct kinase for 4E-BP1, we first used protein kinase specificity prediction programs. Interestingly, they predicted that CK1 could phosphorylate 4E-BP1 at T41 (TPGGT
41
) and T50 (TPGGT 50 ), which have the same sequence and are conserved in 4E-BP2 and 4E-BP3 (Fig. 5E ). To determine if CK1İ could bind to 4E-BP1 in cells, we performed immunoprecipitation. As shown in Fig. 5F , CK1İ interacted with 4E-BP1. We also used purified 4E-BP1 from E. coli and confirmed that CK1İ interacted with 4E-BP1 (Fig. S4) . We next performed in vivo interaction assay using breast cancer tissue. As shown in Fig. 5G , CK1İ coimmunoprecipitated with 4E-BP1. These results suggest that CK1İ interacts with 4E-BP1 in vitro and in vivo. We next performed a kinase assay to determine whether CK1İ could phosphorylate 4E-BP1 at T41/T50. As shown in Fig. 5H , CK1İ significantly increased phosphorylation of wildtype 4E-BP1, while it slightly increased phosphorylation of T41A/T50A mutant 4E-BP1. We also used purified recombinant 4E-BP1 from E. coli and found that CK1İ dramatically increased phosphorylation of wild-type 4E-BP1 compared to T41A/T50A 4E-BP1 (Fig. S5 ). All together, these results suggest that CK1İ is a direct kinase that phosphorylates 4E-BP1 at T41/T50.
4E-BP1 phosphorylation at T41/T50 is essential for 4E-BP1 activity.
Little is known about the function and regulation of 4E-BP1 phosphorylation at T41/T50. By stable isotope labeling in cell culture (SILAC), we recently found that T41 and T50 are phosphorylation sites in 4E-BP1 (29) (30) . Other reports have also confirmed the phosphorylation of 4E-BP1 at T41 and T50 under various conditions (31-35), which is also listed in the Cell Signaling Technology PhosphoSitePlus (www.phosphosite.org), database of phosphorylation sites. Therefore, we were interested in performing further studies on the function of T41/T50 phosphorylation. When expressed in HEK293 cells, the T41A/T50A mutant showed a dramatic decrease of phosphorylation at T37/46, T70, and S65 (Fig. 6A) 13 necessary for 4E-BP1 activity, we first performed a cap-binding assay. As shown in Fig. 6B , the T41A/T50A mutant showed more cap-binding compared to WT 4E-BP1, suggesting that T41A/T50A is more active to inhibit eIF4E activity compared to WT 4E-BP1 in serum-growing cells. We observed the same phenomena in different conditions. As shown in Fig. 6C , insulin treatment did not increase S65 phosphorylation in the T41A/T50A mutant. We also performed a cap-binding assay. As shown in Fig. 6D , WT 4E-BP1 became inactivated and dissociated from eIF4E after insulin treatment. However, the T41A/T50A mutant was still bound to eIF4E after stimulation with insulin, suggesting that the T41A/T50A mutant is active even in the presence of insulin (Fig. 6D) . These results suggest that 4E-BP1 phosphorylation at T41/T50 is critical for phosphorylation at S65 and 4E-BP1 activity. We next examined proliferation of cells expressing the T41A/T50A mutant and found that this mutation inhibited cell proliferation in HEK293 cells (Fig. 6E) . To find if this also affects tumor growth, we injected stable HCC1806 cells expressing the T41A/T50A mutant into mice. As shown in Figs. 6F and 6G, this mutant significantly affected tumor growth in mice.
CK1İ regulates cap-dependent translation and cell proliferation by regulating 4E-BP1.
Because CK1İ inhibition activated 4E-BP1 and prevented dissociation of 4E-BP1 from eIF4E, we hypothesized that CK1İ inhibition would not affect 4E-BP1-dependent eIF4E activity, translation, and cell proliferation in the presence of very low 4E-BP1 levels. To determine whether CK1İ regulates protein synthesis by regulating 4E-BP1, we used stable 4E-BP1 knockdown cells (Fig. 7A) . Unlike the control cells, CK1İ inhibitor treatment did not profoundly inhibit nascent protein synthesis in 4E-BP1 knockdown cells (Fig. 7B) . We also examined whether the CK1İ effect on cap-dependent translation and cell proliferation is dependent on 4E-BP1. For this, stable control or 4E-BP1 knockdown cells were treated with CK1İ inhibitor. As shown in Fig. 7C and 
Discussion
Deregulation of mRNA translation is directly associated with many pathological conditions such as cancer and neurological disorders, suggesting that a better understanding of the mechanism involved in this process is of great physiological and pathological importance.
Because eIF4E is a rate-limiting factor for cap-dependent mRNA translation, its inhibitor, 4E-BP1, is a critical negative regulator of cancer progression. Phosphorylation status and amount of 4E-BP1 strongly correlate with the survival of cancer patients (36) . Cancer patients in which 4E-BP1 is highly phosphorylated or expressed in low amounts exhibit poor survival rates (37) . In addition to its role in cancer progression, 4E-BP1 is also a critical regulator of life span and aging (13, 38) . In light of the roles that 4E-BPs play as tumor suppressors and aging modulators, it is of great importance to identify signaling pathways that regulate 4E-BP phosphorylation (37).
Here we showed that CK1İ is a key regulator of 4E-BP1 function. CK1İ had previously been implicated in the regulation of developmental pathways and circadian rhythms (39) (40) .
Recently, CK1İ has gained attention for its oncogenic role, and CK1İ was identified as a therapeutic target in MYC-driven cancers (19) . Along with this, it is known that CK1İ is highly expressed in many cancer types and that it promotes tumorigenesis and tumor progression by regulating circadian rhythm proteins and Wnt signaling (16, 39) . Considering the roles of 4E-BP1 and mRNA translation in cancer progression, our results that CK1İ is a major regulator of 4E-BP1 and mRNA translation suggest that targeting CK1İ could benefit cancer patients characterized by aberrant eIF4E/4E-BP1 regulation. It will be of interest to test whether CK1İ targeting alone or in combination with mTOR inhibitors could overcome the resistance of cancer cells against mTOR inhibitors. It will also be interesting to examine if CK1İ-mediated 4E-BP1 regulation and its targeting lead to modulation of aging and age-related diseases since 4E-BP1, circadian rhythm, and mRNA translation are already known to significantly modulate life span and aging. CAN-13-1175 Because of the critical role of 4E-BP1 in mRNA translation and cell proliferation, its phosphorylation is highly regulated. It is known that S65 is highly dependent on the mTORC1 pathway (28) . The phosphorylation of T70 is complicated and controversial (41) (42) . The currently accepted mechanism of 4E-BP1 inactivation is that T37/T46 are phosphorylated first, and T70 and S65 are phosphorylated in a stepwise fashion upon stimulation with growth factors and hormones (27) . Here we showed that T41/T50 are phosphorylated by CK1İ, which is required for the phosphorylation of T37/T46, T70, and S65, thereby regulating 4E-BP1 activity and cap-binding translation. Interestingly, CK2, another casein kinase, was shown to phosphorylate a site in the C-terminal region of 4E-BP1 (43) . Taken together, it seems that casein kinases and mTORC1 cooperate to fully inactivate 4E-BP1 and initiate mRNA translation.
Although most protein kinases are generally tightly controlled signaling molecules that are switched on in response to specific stimuli (44), a few kinases are constitutively active irrespective of cellular context. These constitutively active kinases are often deeply involved in the activation of many regulatory molecules or they cooperate with many regulatory kinases for the full function of their substrates. CK1 is one of a few constitutively active unregulated kinases, although it was recently suggested that CK1 could be regulated by its binding partners (45) .
Here we show that CK1İ is a critical factor that regulates mRNA translation and cancer progression. It is known that CK1İ is highly overexpressed in many cancers. Therefore, our results suggest that highly overexpressed constitutively active CK1İ in cancers could accelerate mRNA translation and tumor progression. Our study underscores the importance of CK1İ as a promising target to treat cancer and other diseases characterized by deregulated protein 
